Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
Publication
, Other
Kelly, WK; Danila, DC; Lin, C-C; Lee, J-L; Matsubara, N; Ward, PJ; Armstrong, AJ; Pook, D; Kim, M; Dorff, TB; Fischer, S; Lin, Y-C; Sumey, C ...
January 12, 2024
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., … Appleman, L. J. (2024). Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. https://doi.org/10.1158/2159-8290.24988595.v1
Kelly, William K., Daniel C. Danila, Chia-Chi Lin, Jae-Lyun Lee, Nobuaki Matsubara, Patrick J. Ward, Andrew J. Armstrong, et al. “Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study,” January 12, 2024. https://doi.org/10.1158/2159-8290.24988595.v1.
Kelly WK, Danila DC, Lin C-C, Lee J-L, Matsubara N, Ward PJ, et al. Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. 2024.
Kelly, William K., et al. Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. 12 Jan. 2024. Crossref, doi:10.1158/2159-8290.24988595.v1.
Kelly WK, Danila DC, Lin C-C, Lee J-L, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin Y-C, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Supplementary Figure S2 from Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. 2024.